Wellness & Lifestyle

Brainify.AI is an AI-powered platform dedicated to advancing brain health through innovative technology. It provides medical-grade EEG devices for accurate data collection, coupled with robust large-scale data analysis capabilities. The platform utilizes advanced predictive modeling to support precision medicine initiatives, aiming to decode complex brain health patterns. This comprehensive approach is designed to aid in the development of novel treatments, particularly for conditions like depression, by increasing the likelihood of new treatment approval and enhancing drug efficacy. Brainify.AI serves as a crucial tool for researchers and medical professionals in the pharmaceutical and biotech sectors.

OM1 is a leading AI outcomes platform specializing in healthcare analytics. Its core offering is the PhenOM AI foundation model, which is trained on over a billion patient-years of data to identify patient phenotypes, accelerate diagnoses, and predict future medical events, risks, and responses to treatment. OM1 also features an Agentic Health Data Framework for automating data capture and enrichment. The platform provides solutions for patient finding, outcomes prediction, clinical registries, automated studies, and data set enrichments. It serves life sciences companies, healthcare providers, and payers, enabling them to make data-driven decisions and improve patient outcomes.

Inato is an AI-powered platform designed to accelerate and improve clinical trials by connecting sponsors, research sites, and patients. It facilitates faster, more inclusive trials by optimizing early planning, site selection, and patient pre-screening. The platform helps sponsors activate diverse, high-performing sites with better planning and enrollment tools, while enabling research sites to win more trial opportunities matched to their capabilities. Inato leverages AI to find qualified sites based on actual capabilities and patient access, and automates chart review and pre-screening to reduce site burden and accelerate patient enrollment. It is built for global impact, operating in over 50 countries with 6,000+ sites and 25+ sponsors.

Integrated Biosciences, Inc. is at the forefront of aging medicine, leveraging a sophisticated Integrated Platform that combines synthetic biology, chemistry, and AI. This platform is designed to unravel the intricate networks of aging, enabling precise and dynamic control of biological targets and pathways. By generating high-fidelity datasets and utilizing advanced AI, the company systematically explores previously inaccessible chemical spaces for small molecule therapeutic discovery. Their core strength lies in ultra-large, in-house aging datasets that fuel target identification. The platform integrates optogenetics for precise biological control, advanced chemistry tools for drug optimization, and a powerful AI engine driven by differentiated datasets. Integrated Biosciences is actively advancing a pipeline of novel small molecule therapeutics for age-related diseases, building on pioneering science from MIT.

DeepChem is an open-source Python library designed to democratize the use of deep learning across various scientific domains, including drug discovery, quantum chemistry, materials science, and biology. It offers a comprehensive toolchain for researchers to apply advanced machine learning techniques to complex scientific problems. The library supports multiple deep learning frameworks like TensorFlow, PyTorch, and JAX, allowing for flexible integration into existing workflows. DeepChem provides extensive tutorials, examples, and documentation, making it accessible for both beginners and experienced practitioners in molecular machine learning and computational biology. It also fosters a strong community through Discord and GitHub, encouraging contributions and discussions among scientists and developers.

Deepful is a specialized AI role-play platform designed for the pharmaceutical industry, focusing on enhancing the commercial excellence of sales representatives and Medical Science Liaisons (MSLs). The platform allows users to practice conversations with AI-powered HCP personas in a safe and realistic environment, building confidence and improving performance. It transforms complex scientific content into engaging, scenario-based training, ensuring accuracy and compliance. Deepful provides tailored insights and performance dashboards, mapping to pharma-specific KPIs like message delivery and scientific accuracy, enabling managers to monitor progress and target coaching effectively. The tool supports continuous practice with minimal oversight, fostering proactive habits and improving field-readiness 24/7.

Anima Biotech's Biology GPU is the first experimental runtime for AI in drug discovery, allowing AI models to interact with cells and reason within biological pathways. This platform utilizes Visual Biology Computing to enable AI models to experimentally 'chat' with cells, providing causal biology resolution across the entire discovery lifecycle. Key capabilities include experimentally resolving active pathways, separating causal drivers from associated passengers, identifying how active molecules work, and understanding off-target effects. The system integrates large-scale experimental infrastructure to execute AI and omics-derived hypotheses directly in cells, interpreting millions of cellular images with a model trained on over 2 billion pathway images across diverse cell types and diseases. The BioGPU agent allows scientists and LLMs to design experiments, run visual compute, and iteratively test hypotheses against observed pathway activity.

iLoF is a digital health company at the forefront of personalized medicine, leveraging a breakthrough AI-platform to accelerate drug discovery and development. Their cloud-based library utilizes optical fingerprints, powered by photonics and AI, to provide non-invasive tracking, screening, and stratification for clinical trials. This innovative approach allows for efficient, flexible, and patient-centric drug development, requiring only microliters of blood and taking less than 10 seconds per sample. The platform aims to reduce costs by 40% and screening time by 70%, while improving the quality of candidate pools. iLoF is currently focusing on Alzheimer's, COVID-19, and Ovarian Cancer, building out its virtual fingerprint library to expand its applications to other diseases.

COGVIO, an IQVIA business, is a technology and data science company dedicated to developing specialized applications for the pharmaceutical, medical device, and healthcare segments. Their flagship product, Price Monitor, is an AI-powered digital tool that integrates over 100 global sources of pricing, reimbursement, and HTA data. This enables market access and pricing teams to gain strategic insights, support payer negotiations, and manage pricing throughout the product life-cycle. COGVIO also offers advanced data analysis services, including RWE analysis and custom project collaboration, and provides pharma and healthcare software development with a strong focus on regulatory compliance like GDPR, GAMP, and HIPPA.

Proteinea is a TechBio company dedicated to advancing biotherapeutics design through the integration of artificial intelligence and biotechnology. The platform employs proprietary AI models and computational tools to engineer next-generation antibodies, focusing on improving their efficacy, safety, and convenience. Proteinea specializes in the rational engineering of antibody Fc domains to enable context-specific immune tuning, enhanced half-life, and targeted biodistribution. Their design frameworks combine AI-driven prediction with therapeutic insight to unlock differentiated immune function. The company also emphasizes the development of modular Fc scaffolds that consider manufacturability, stability, pharmacokinetics, and delivery, aiming to reduce downstream failure and accelerate the path-to-patient. Proteinea's experimental workflows are tailored for rapid testing of Fc designs, bridging computational design with biological reality through smart wet-lab validation.

Relation Therapeutics is an end-to-end biotech company focused on discovering and developing transformational medicines. The company utilizes cutting-edge technology, including single-cell multi-omics directly from patient tissue, functional assays, and machine learning, to gain an unprecedented understanding of human biology. This integrated approach, termed 'Lab-in-the-Loop,' drives disease understanding from cause to cure, enabling the selection of druggable targets and the development of innovative therapies. Relation's interdisciplinary team comprises experienced drug developers, computational scientists, and entrepreneurs dedicated to revolutionizing drug development.

CellCo, also known as The Cell Company, is a therapeutics company dedicated to engineering breakthrough medicines. They achieve this by integrating advanced molecular simulation techniques with artificial intelligence. The company's core focus is on deep technology development, aiming to innovate in the pharmaceutical and biotech sectors. Their approach involves using AI to model and engineer biological systems, which is crucial for the discovery and development of novel therapeutic solutions. CellCo is actively expanding its team and capabilities to further its mission of creating impactful medicines.

Neuralgap is an AI-driven platform dedicated to supporting biotech startups by integrating cutting-edge AI research into drug discovery and development. The platform features the Genesys Model Family, which offers built-in transparency, multimodal architecture for proteins, peptides, and small molecules, and efficient design requiring significantly less training data and compute. Neuralgap also provides Circe, an agentic intelligence that delivers insight into AI's thought processes. The tool supports custom deep learning builds for Pharma clients, covering structure evaluation, hit discovery and optimization, and lead optimization and candidate selection. It aims to accelerate research and drive scientific breakthroughs in the biotech sector.

Ryght AI transforms clinical trial site selection and feasibility by leveraging AI Site Twins, which are digital replicas of every research site globally. This platform drastically shortens traditional timelines by rapidly analyzing protocols and instantly connecting users with high-potential research sites worldwide. It streamlines site selection, accelerates activation, and optimizes site performance throughout the trial duration. Key features include AI-powered analysis of complex datasets, simulation and forecasting of enrollment performance, and dynamic updates to site twins with real-time data. Ryght AI is available on the Microsoft Azure Marketplace, allowing sponsors and CROs to utilize existing cloud commitments and increase cost efficiency.

Think Touch Solution is a consulting firm dedicated to assisting pharmaceutical and healthcare companies in Algeria and other African countries. Founded in 2022, the company offers expertise in pharmacovigilance, regulatory affairs, market research, information technology, and artificial intelligence. They provide strategic insights and innovative, compliant solutions to help clients introduce innovations while adhering to regulatory changes. Their services include end-to-end support for regulatory submissions, digital health strategy, and market access planning, with a focus on leveraging AI and analytics to identify safety signals and mitigate risks. They also organize industry events to foster connections and learning within the pharma and healthcare sectors.

TraitSeq is an AI-based technology platform designed to accelerate complex trait development in agriculture. It empowers agritech companies by providing insights to decode complex traits and models to predict performance during product development, leading to faster time to market and higher success rates. The platform achieves this by creatively combining proprietary machine learning algorithms with RNA-Seq data to uncover predictive biomarkers. Key offerings include cutting-edge machine learning for actionable predictions, transcriptome analysis to connect gene expression data with phenotypes, and biomarker identification through tailored experimental designs and advanced data analysis. TraitSeq's solutions are applicable across crop protection, biostimulants, gene editing, engineering, trait discovery, and pathway analysis.

LLaVA-Med is a Large Language-and-Vision Assistant for Biomedicine, developed by Microsoft, that aims to achieve multimodal GPT-4 level capabilities in the biomedical domain. It leverages visual instruction tuning and is continuously trained using a curriculum learning approach, starting with general-domain LLaVA and then specializing in biomedical concept alignment and instruction-tuning. The tool is open-sourced under the MSR release policy and is intended for research use only, specifically for advancing visual-language processing and visual question answering in biomedicine. It is expressly prohibited for use in clinical care or for any clinical decision-making purposes. LLaVA-Med is built upon the PMC-15M dataset, which comprises 15 million figure-caption pairs from biomedical research articles, covering diverse image types like microscopy, radiography, and histology.

DaltonTx redefines drug discovery by providing an AI-enabled platform that serves as an intelligence backbone for modern R&D. It offers an adaptive intelligent system that evolves with scientific advancements, integrates seamlessly into existing workflows, and empowers users with lasting capabilities. The platform learns from every scientist, model, and experiment, continuously improving and guiding better decisions. DaltonTx's technology covers the full discovery lifecycle, including data ingestion, model training, molecule generation, and experiment prioritization. It is built by scientists for scientists, combining software engineering, machine learning, and deep drug discovery expertise to tackle complex problems in both small molecules and biologics.

Enveda is a biotechnology company leveraging AI to revolutionize drug discovery. The platform reads and translates nature's hidden chemistry at unprecedented speed and scale, enabling scientists to access the chemical diversity of the natural world for the first time. By identifying and characterizing molecules found in nature, Enveda aims to discover medicines 4X faster than the industry average. This approach addresses the traditional challenges of purifying, identifying, and characterizing natural molecules, which are often time-consuming and costly. Enveda's mission is to accelerate the discovery of better medicines, offering hope to millions globally by harnessing billions of years of evolutionary intelligence.

Healx is a pioneering technology company dedicated to accelerating the discovery and development of treatments for rare diseases. Leveraging advanced AI and other frontier technologies, Healx redevelops, combines, and enhances known compounds to build a robust pipeline of new and effective therapies. The platform rapidly identifies novel drug-disease relationships with the highest chance of success, de-risking the drug discovery process and enabling parallel program execution. This approach aims to address the significant unmet need for treatments, as 90% of the over 10,000 rare diseases currently lack effective therapies. Healx collaborates with partners to progress treatments from prediction to patient.

reprai transforms the promotional landscape for pharmaceutical companies by leveraging AI-powered technology to optimize communication with healthcare professionals. The platform offers features like AI-driven human interaction mimicry for personalized content, advanced real-time data segmentation for targeted content delivery, and seamless integration for training material creation. It also provides comprehensive dashboards and reporting for deep insights into promotional activities, enabling data-driven decisions and continuous strategy improvement. reprai aims to redefine pharma engagement with AI precision, offering a streamlined and effective process for complex promotional operations.

Algorae Pharmaceuticals (ASX: 1AI) is an Australian pharmaceutical company operating at the intersection of commercial supply and R&D. The company has two main divisions: AlgoraeRx and AlgoraeOS. AlgoraeRx focuses on sourcing and supplying generic and specialty medicines to the Australian and New Zealand markets through partnerships with global manufacturers. AlgoraeOS is their proprietary AI-powered drug discovery platform, built in collaboration with UNSW AI Institute and CSIRO Data 61, and independently validated by the Peter MacCallum Cancer Centre. This platform generates high-confidence drug-combination candidates for licensing and co-development, providing a continuously developing pipeline of novel programs. Algorae Pharmaceuticals aims to address medicine supply problems in Australia while developing innovative pharmaceutical solutions through AI.

Iktos leverages cutting-edge AI and robotics to transform drug discovery, aiming to reduce timelines to under 24 months. Its platform integrates Generative AI (Makya) for de novo drug design, focusing on synthetic accessibility and multi-parametric optimization, and AI-driven retrosynthesis (Spaya) to identify feasible synthetic routes. The process is further enhanced by Iktos Robotics, which manages automated synthesis, purification, analysis, and testing, creating a fully autonomous lab environment. This integrated approach supports the entire molecular journey from inception to drug candidate, iterating through the DMTA cycle and optimizing molecular properties with multidimensional biological data.

[RE]MEDs is an AI-powered platform dedicated to the real-life repurposing and repositioning of medicines, with a primary focus on autoimmune disorders. The platform utilizes a unique AI-powered technology to study thousands of drugs in-silico, analyzing billions of electronic medical records and health datasets. This advanced approach aims to identify new cures for diseases with unmet medical needs, particularly within the autoimmune space, which affects over 100 million people globally. [RE]MEDs investigates the effects of the vast majority of drugs (99%) that are not specifically designed for autoimmune diseases but are still used by patients, seeking to understand their impact and potentially discover new therapeutic applications. The research covers a wide range of autoimmune conditions including Systemic Lupus, Multiple Sclerosis, Rheumatoid Arthritis, and Type 1 Diabetes Mellitus.